Compare ASML & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASML | AZN |
|---|---|---|
| Founded | 1984 | 1992 |
| Country | Netherlands | United Kingdom |
| Employees | 44209 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.2B | 316.4B |
| IPO Year | 1995 | 1995 |
| Metric | ASML | AZN |
|---|---|---|
| Price | $1,848.62 | $157.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $1,460.63 | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 3.7M |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | 0.54% | ★ 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.80 | $10.34 |
| Revenue Next Year | $19.51 | $6.43 |
| P/E Ratio | $50.62 | ★ $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $718.23 | $72.90 |
| 52 Week High | $1,999.96 | $212.71 |
| Indicator | ASML | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 35.29 |
| Support Level | $1,717.00 | $153.41 |
| Resistance Level | $1,979.50 | $209.98 |
| Average True Range (ATR) | 60.42 | 3.15 |
| MACD | 20.30 | -0.33 |
| Stochastic Oscillator | 92.97 | 17.56 |
ASML is the leader in lithography systems for manufacturing semiconductors with 90% market share. Lithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's largest clients are TSMC, Samsung, Intel, SK Hynix, and Micron.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.